Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration

Status unconfirmed · Phase 1

Conditions studied: Neovascular Age Related Macular Degeneration

In brief

Age-related macular degeneration (AMD) is a disease that, in time, destroys the macula, which is the central part of the retina that gives sharp central vision. The primary purpose of this study is to assess the safety of iSONEP which is a humanized monoclonal antibody against a bioactive lipid, sphingosine 1-phosphate (S1P).

Key facts

Study ID

NCT00767949

Run by

Lpath, Inc.

People needed

15

Starts

2008-10-01

Expected to finish

2012-08-01

Last updated by the study team

2012-04-16

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 50 years and older
• BCVA ETDRS letter score in study eye between 20-57 letters using ETDRS refraction (Snellen of 20/70-20/400)
• Any CNV secondary to AMD in study eye, classic, minimally classic or occult with leakage on fluorescein angiography and intraretinal or subretinal fluid on OCT
• Visual acuity in fellow eye must be 20/800 or better at 4 meters
• Able to read, understand and sign the consent form before entering into study

You may not qualify if…

• Ocular disease other than CNV that could compromise vision in study eye
• Systemic immunosuppressive medication/therapy (e.g., chemotherapy, steroids)
• Uncontrolled hypertension and/or arrhythmias
• QT/QTc interval measurement >450 msec
• Cancer within the last 2 years except superficial basal or squamous cell skin cancer or cervical carcinoma in situ
• Have angioid streaks, presumed ocular histoplasmosis syndrome, myopia (>8 diopters) or CNV secondary to other causes than AMD
• Any additional ocular diseases which have irreversibly compromised visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema and severe non-proliferative diabetic retinopathy
• Any intraocular or general surgery, including cataract surgery, within 2 months of Day 1
• History of uveitis in either eye
• Any ocular or periocular infection within 4 weeks prior to Day 1
• Active ocular inflammation grade trace and above
• Cup to disc ratio >0.8, IOP >21 mmHg in glaucoma subjects treated with more than 2 ocular hypotensive agents
• Previous pars plana vitrectomy or trabeculectomy in study eye
• History of anterior vitrectomy
• Inability to obtain photographs, FA or OCT to document CNV, e.g. due to media opacity, allergy to fluorescein dye or lack of venous access
• Aphakia
• Previous intravitreal Macugen, Avastin or Lucentis (injection or drug device implantation) in study eye within 6 weeks or triamcinolone within 6 months
• Receiving or requiring chronic concomitant therapy with systemic anti-angiogenic treatments p.o., parenteral (excluding inhaled steroids) (>5 mg) or topical corticosteroids in the study eye
• PDT within 12 weeks prior to Day 1
• Subjects taking systemic anticoagulants such as warfarin
• Investigational agents or devices within 6 weeks prior to Day 1
• Females who are pregnant or nursing and women of child bearing potential who are not using adequate contraceptive precautions

Where it is running

• Retinal Consultants of Arizona, LTD — Phoenix, Arizona, United States
• Center for Retina and Macular Disease — Winter Haven, Florida, United States
• Midwest Eye Institute — Indianapolis, Indiana, United States
• Vitreo-Retinal Consultants — Grand Rapids, Michigan, United States
• Wills Eye Institute — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.